Epigenomics OTC Stock Today


USD 0.39  0.00  0.00%   

Market Performance
0 of 100
Odds Of Distress
Over 83
Epigenomics is trading at 0.39 as of the 14th of August 2022, a No Change since the beginning of the trading day. The stock's lowest day price was 0.39. Epigenomics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Epigenomics Ag Berli are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 15th of June 2022 and ending today, the 14th of August 2022. Click here to learn more.
Fiscal Year End
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany. Epigenomics operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. The company has 16.36 M outstanding shares. More on Epigenomics Ag Berli

Moving against Epigenomics

0.63ENPHEnphase Energy TrendingPairCorr
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Epigenomics OTC Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Epigenomics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Epigenomics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Epigenomics Ag Berli generated a negative expected return over the last 90 days
Epigenomics Ag Berli has some characteristics of a very speculative penny stock
Epigenomics Ag Berli has high historical volatility and very poor performance
Epigenomics Ag Berli has a very high chance of going through financial distress in the upcoming years
The company reported the revenue of 6.21 M. Net Loss for the year was (3.88 M) with profit before overhead, payroll, taxes, and interest of 6.07 M.
Epigenomics Ag Berli has accumulated about 20.04 M in cash with (5.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.25, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 37.0% of the company shares are held by company insiders
CEOGregory Hamilton
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Epigenomics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellOvervalued
Epigenomics Ag Berli [EPGNF] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Nano-Cap' category with current market capitalization of 7.88 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Epigenomics's market, we take the total number of its shares issued and multiply it by Epigenomics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Epigenomics Ag Berli classifies itself under Healthcare sector and is part of Diagnostics & Research industry. The entity has 16.36 M outstanding shares. Epigenomics Ag Berli has accumulated about 20.04 M in cash with (5.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.25, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Epigenomics Probability Of Bankruptcy
Epigenomics Ag Berli retains a total of 16.36 Million outstanding shares. Epigenomics Ag Berli retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Epigenomics Ownership Details

Epigenomics Stock Price Odds Analysis

What are Epigenomics' target price odds to finish over the current price? Based on a normal probability distribution, the odds of Epigenomics jumping above the current price in 90 days from now is about 76.65%. The Epigenomics Ag Berli probability density function shows the probability of Epigenomics otc stock to fall within a particular range of prices over 90 days. Assuming the 90 days horizon Epigenomics Ag Berli has a beta of -0.3253 suggesting as returns on benchmark increase, returns on holding Epigenomics are expected to decrease at a much lower rate. During the bear market, however, Epigenomics Ag Berli is likely to outperform the market. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Epigenomics Ag Berli is significantly underperforming DOW.
  Odds Below 0.39HorizonTargetOdds Above 0.39
23.26%90 days
Based on a normal probability distribution, the odds of Epigenomics to move above the current price in 90 days from now is about 76.65 (This Epigenomics Ag Berli probability density function shows the probability of Epigenomics OTC Stock to fall within a particular range of prices over 90 days) .

Epigenomics Ag Berli Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Epigenomics market risk premium is the additional return an investor will receive from holding Epigenomics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Epigenomics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Epigenomics' alpha and beta are two of the key measurements used to evaluate Epigenomics' performance over the market, the standard measures of volatility play an important role as well.

Epigenomics Stock Against Markets

Picking the right benchmark for Epigenomics otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Epigenomics otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Epigenomics is critical whether you are bullish or bearish towards Epigenomics Ag Berli at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Epigenomics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Bollinger Bands Now


Bollinger Bands

Use Bollinger Bands indicator to analyze target price for a given investing horizon
All  Next Launch Module

Epigenomics Corporate Management

Elected by the shareholders, the Epigenomics' board of directors comprises two types of representatives: Epigenomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Epigenomics. The board's role is to monitor Epigenomics' management team and ensure that shareholders' interests are well served. Epigenomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Epigenomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Antje Zeise - Manager Investor RelationsProfile
Guenther Reiter - Member of the Supervisory BoardProfile
Ann Kessler - Member of the Supervisory BoardProfile
Helge Lubenow - Member of the Supervisory BoardProfile

Invested in Epigenomics Ag Berli?

You need to understand the risk of investing before taking a position in Epigenomics. The danger of trading Epigenomics Ag Berli is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Epigenomics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Epigenomics. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Epigenomics Ag Berli is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Continue to Investing Opportunities. Note that the Epigenomics Ag Berli information on this page should be used as a complementary analysis to other Epigenomics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Complementary Tools for Epigenomics OTC Stock analysis

When running Epigenomics Ag Berli price analysis, check to measure Epigenomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Epigenomics is operating at the current time. Most of Epigenomics' value examination focuses on studying past and present price action to predict the probability of Epigenomics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Epigenomics' price. Additionally, you may evaluate how the addition of Epigenomics to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Is Epigenomics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Epigenomics. If investors know Epigenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Epigenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
7.8 M
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Epigenomics Ag Berli is measured differently than its book value, which is the value of Epigenomics that is recorded on the company's balance sheet. Investors also form their own opinion of Epigenomics' value that differs from its market value or its book value, called intrinsic value, which is Epigenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Epigenomics' market value can be influenced by many factors that don't directly affect Epigenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Epigenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine Epigenomics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Epigenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.